Japanese biotech company AnGes Inc said on Tuesday it had initiated a phase 2/3 clinical trial of its DNA-based COVID-19 vaccine candidate.
The study is taking place at eight facilities in eastern and western Japan involving 500 test subjects, the company said in a statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.